Department of Immunology and Pathology, Monash University, Melbourne, Australia; Immunology Program, The Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom
Carly E Whyte
Immunology Program, The Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom
Silvia Innocentin
Immunology Program, The Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom
Jia Le Lee
Immunology Program, The Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom
James Dooley
Immunology Program, The Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom
Jiong Wang
Division of Nephrology, Department of Medicine and Clinical and Translational Science Institute, University of Rochester Medical Center, Rochester, United States
Eddie A James
Benaroya Research Institute at Virginia Mason, Translational Research Program and Tetramer Core Laboratory, Seattle, United States
James C Lee
Department of Medicine, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom
William W Kwok
Benaroya Research Institute at Virginia Mason, Diabetes Program, Seattle, United States; Department of Medicine, University of Washington, Seattle, United States
Martin S Zand
Division of Nephrology, Department of Medicine and Clinical and Translational Science Institute, University of Rochester Medical Center, Rochester, United States
Adrian Liston
Immunology Program, The Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom
Immunology Program, The Babraham Institute, Babraham Research Campus, Cambridge, United Kingdom; Department of Medicine, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom
Antibody production following vaccination can provide protective immunity to subsequent infection by pathogens such as influenza viruses. However, circumstances where antibody formation is impaired after vaccination, such as in older people, require us to better understand the cellular and molecular mechanisms that underpin successful vaccination in order to improve vaccine design for at-risk groups. Here, by studying the breadth of anti-haemagglutinin (HA) IgG, serum cytokines, and B and T cell responses by flow cytometry before and after influenza vaccination, we show that formation of circulating T follicular helper (cTfh) cells was associated with high-titre antibody responses. Using Major Histocompatability Complex (MHC) class II tetramers, we demonstrate that HA-specific cTfh cells can derive from pre-existing memory CD4+ T cells and have a diverse T cell receptor (TCR) repertoire. In older people, the differentiation of HA-specific cells into cTfh cells was impaired. This age-dependent defect in cTfh cell formation was not due to a contraction of the TCR repertoire, but rather was linked with an increased inflammatory gene signature in cTfh cells. Together, this suggests that strategies that temporarily dampen inflammation at the time of vaccination may be a viable strategy to boost optimal antibody generation upon immunisation of older people.